Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Neuroendocrine cancer (also known as NETs) is a cancer type that arises from cells of the neuroendocrine system (cells that release hormones in our body). They are classified according to where the primary tumour originated from, and the most common types are gastrointestinal, lung or pancreatic NETs.
Single immune checkpoint blockade has shown limited activity in patients with neuroendocrine neoplasms (NENs). Here the authors report the results of a phase II clinical trial of durvalumab (anti-PD-L1) and tremelimumab (anti CTLA-4) in patients with advanced NENs of gastroenteropancreatic and lung origin.
